News Room

A collection of press releases, audio content and media clips featuring INFORMS members and their research.

INFORMS Applauds Passage of Historic Legislation to Modernize STEM Education
News Release

BALTIMORE, MD, September 26, 2024 – In overwhelming bipartisan fashion, the U.S. House of Representatives just passed the “Mathematical and Statistical Modeling Education Act,” (H.R. 1735) which, if enacted, would modernize STEM education in the United States. The bill passed by unanimous consent.

Read More
Closing the Racial Gap in CRC: Screening is Just the First Step
Media Coverage

Too many people in the United States are dying of colorectal cancer (CRC). The #2 cancer killer in the United States, it impacts Black Americans disproportionately. Compared to White adults, Black adults aged 50 and above get colon cancer at a rate that’s 23% higher than White adults and have a 31% higher risk of dying from the disease.1 These disparities persist despite progress in screening and treatment and are particularly frustrating because CRC is highly treatable when caught in early stages and even preventable when pre-cancers are identified and removed through screening. These differences in incidence and mortality persist even while we have made progress to make screening more accessible to all. A 2019 NIH study showed that a similar proportion of Black and White Americans are up to date with CRC screening2, a meaningful improvement since 20053. If screening access and uptake are now so similar, why do these disparities persist?  

Read More
Big Government and Big Tech both want your biometric data
Media Coverage

Both Amazon and the Transportation Security Administration (TSA) are demanding the biometric data of all Americans.

Read More

Resoundingly Human Podcast

An audio journey of how data and analytics save lives, save money and solve problems.

Media Contact

Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578

INFORMS in the News

What are you looking for?

Type of Content
Topic
Some Companies Will Make Big Money Off Their COVID-19 Vaccines - But Not as Much as They Could

Some Companies Will Make Big Money Off Their COVID-19 Vaccines - But Not as Much as They Could

CBC, November 25, 2020

While the development of a COVID-19 vaccine could generate billions of dollars for some pharmaceutical companies such as Pfizer, concerns over accusations of exploiting the pandemic will likely temper profits, experts suggest. "It doesn't really make sense to profit from this pandemic," said Tinglong Dai, associate professor of operations management and business analytics at Johns Hopkins University Carey Business School in Baltimore.

What's the Science Behind COVID Business Capacity Limits?

What's the Science Behind COVID Business Capacity Limits?

Las Vegas Review-Journal, November 25, 2020

New restrictions imposed on restaurants and other businesses this week by Gov. Steve Sisolak to curb the spread of COVID-19 raise a question: What’s the science behind them? The science is imperfect, broad in stroke and balanced by policy and political considerations, health authorities said. “The basic idea is we are trying to reduce the density of people in any environment,” said epidemiologist Brian Labus, a member of the governor’s medical advisory team on COVID-19.

Vaccine Resisters Could Derail Island's COVID-19 Recovery, Experts Say

Vaccine Resisters Could Derail Island's COVID-19 Recovery, Experts Say

Newsday, November 29, 2020

Delivering an effective vaccine is only part of the equation. The region's recovery from COVID-19 also will hinge on Long Islanders' willingness to take the shot, experts say. The public's appetite for inoculations will be a wild card, said Julie Swann, an expert in health care supply chains who advised the Centers for Disease Control and Prevention during the H1N1 outbreak in 2009.

Pfizer's COVID Vaccine Comes With a Chilly Complication. But That May Change.

Pfizer's COVID Vaccine Comes With a Chilly Complication. But That May Change.

Fortune, November 28, 2020

Pfizer’s coronavirus vaccine candidate, announced earlier this month, comes with a major complication that could delay its distribution in rural areas and developing countries: It must be stored at the ultra-cold temperature of -70°C. That means the vaccine must be kept in specialized freezers that cost as much as $20,000 each and are rare outside of medical research facilities.

What Will It Take to Get a COVID-19 Vaccine to the World?

What Will It Take to Get a COVID-19 Vaccine to the World?

New Scientist, November 18, 2020

In Kalamazoo, Michigan, millions of vials of a covid-19 vaccine may soon be rolling off production lines. There are still many hurdles to leap before that vaccine – the candidate from US drug company Pfizer and its German partner BioNTech – or any other is approved and distributed, but governments, manufacturers and shipping firms around the world have already spent months preparing for what happens next.

Subject Matter Experts in

Supply Chain

View list of experts

Subject Matter Experts in

Healthcare

View list of experts

INFORMS Magazines

OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.

Access OR/MS Today Magazine

Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.

Access Analytics Magazine